The Lipo C blend , with its multi-component formulation including lipotropic agents like choline, inositol, and methionine alongside L-carnitine , is an attractive subject for studies aiming to understand complex metabolic interactions and provide holistic support for liver function and fat mobilization
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
The STEP 2 trial, published in The Lancet , focused on individuals with both obesity and type 2 diabetes
Jeans load the gun and the environment pulls the trigger